Kai Henrik Barck1, Anthony Lima2,
Tim Cao1, Rafael Molina2, William F. Forrest3,
Weilan Ye4, Leisa Johnson2, Richard A. D. Carano1
1Biomedical Imaging, Genentech,
South San Francisco, CA, United States; 2Molecular Biology,
Genentech, South San Francisco, CA, United States; 3Biostatistics,
Genentech, South San Francisco, CA, United States; 4Tumor Biology
& Angiogenesis, Genentech, South San Francisco, CA, United States
Our goal was to evaluate the vascular effects of anti-VEGF-A treatment in a Genetically Engineered Mouse Model of Non-small Cell Lung Cancer with respiratory-gated DCE-MRI. Small (Gd-DTPA) and intermediate (Gadomer 17) molecular weight contrast agents were compared. With Gadomer 17, both Ktrans (meanSEM: -458% vs. 79%, p<0.001) and IAUC180 (-295% vs. 46%, p<0.001) decreased significantly in mice treated with anti-VEGF compared to control, but not with Gd-DTPA. This strong anti-VEGF response is consistent with drug efficacy in this model. Gadomer 17 was found to be more suitable for DCE-MRI in this model, likely due to its slower extravasation.